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Frontotemporal dementia: a peek under its invisibility cloak
Frontotemporal dementia is a group of neuro-
degenerative diseases1 that eat away at our core being. 
Like its comrade, Alzheimer’s disease, ageing is its best 
friend. Patients and families tell tales of behavioural 
changes that sometimes encroach on the incredible: 
“Mummy threw her faeces at me this morning, doc”. 
Language can also be lost.2 Words like “dog”, “eyes”, and 
“thing” are retained, whereas words like “equestrian”, 
“aardvark”, and “asparagus” are meaningless. With 
progression, eventually only the shell of a person lingers 
on, until death ensues. This disease not only steals 
individual lives, but also can target families. In some 
instances, family members can be aﬄ  icted with motor 
neuron disease, which can be even more devastating than 
frontotemporal dementia.3 The ﬁ rst genetic mutation 
causing frontotemporal dementia was reported more 
than a decade ago.4 Three major genetic abnormalities are 
now recognised: mutations in the microtubule-associated 
protein tau and the progranulin genes, and repeat 
expansions in the C9orf72 gene. Mutations in these three 
genes account for most genetic abnormalities identiﬁ ed 
in frontotemporal dementia5 and have diﬀ ering clinical,6 
neuroanatomical,7 and neuropathological associations.8 
Like all neurodegenerative disease, by the time the 
patient becomes aﬀ ected, irreversible changes are likely 
to have already been set in motion. Atrophy can already 
be detected, predominantly in the frontal and temporal 
lobes.9 By then, it is probably too late. Unfortunately, most 
published studies in frontotemporal dementia investigate 
patients who are already symptomatic. The missing 
piece is the presymptomatic stage, when symptoms, and 
even signs, are essentially invisible. Understanding this 
presymptomatic stage is crucial if therapeutic measures 
are to be helpful to patients with the disease. The dilemma 
is how to identify such patients. One solution is to study 
aﬀ ected families in which genetic status is known. Such 
studies provide three classes of participants: those without 
a mutation; those with a mutation who are symptomatic; 
and those with a mutation who are presymptomatic. 
In The Lancet Neurology, Rohrer and colleagues10 
capitalise on the value of familial studies to peek under 
the cloak of invisibility of the presymptomatic stage 
of frontotemporal dementia. The investigators, from 
the UK, Europe, and Canada, pooled and analysed 
clinical, neuropsychological, and neuro imaging data 
from 220 genetically characterised participants: 
118 carriers of mutations associated with frontotemporal 
dementia and 102 non-carriers who were relatives of 
symptomatic carriers. With an interesting approach to 
analysis, the investigators used mixed-eﬀ ects models 
to estimate the earliest points in time that clinical or 
neuroimaging abnormalities could be identiﬁ ed. One 
of the key ﬁ ndings of the study was the identiﬁ cation 
of regional neuroimaging changes on MRI as much as a 
decade before predicted age of onset. Not surprisingly, 
neuroimaging abnormalities predated neuropsychological 
deﬁ cits by 5 years. The major strength of this study, 
other than assessment of presymptomatic patients, is 
its multicentre design, which produced large numbers 
of participants to be analysed, including 78 people who 
were asymptomatic at the time of assessment. These 
large numbers allowed for elaborate statistical analysis 
and provided power to detect subtle abnormalities. Some 
people will certainly quibble about the methods used for 
estimation of expected symptoms onset—calculation 
of average onset for each family on the basis of aﬀ ected 
family members—but unless a better approach can be 
proposed, this method is as good as it can be with use of 
cross-sectional data for longitudinal prediction. 
One of the main impetuses for this study is the search 
for the holy grail of neurodegenerative diseases—
biomarkers. Although neuroimaging biomarkers seem, 
impressively, to be able to detect change a decade before 
disease onset in this study, genetic testing will always 
be king of the biomarker arena. However, this fact 
should not downplay the importance of neuroimaging. 
Neuroimaging biomarkers enable change to be measured 
over time, which is one of the important attributes of 
outcome measures used in therapeutic trials; to show a 
reduction in progression is typically necessary to prove 
pharmacological eﬃ  cacy. Therefore, if we are to stamp out 
frontotemporal dementia, a biomarker that can detect 
change in the presymptomatic stage of disease is not only 
useful, but essential. As these presymptomatic individuals 
are studied over time, the investigators should be able to 
provide us with longitudinal data to validate their cross-
sectional predictions. The discipline of frontotemporal 
dementia has been fast moving with many advances over 
the past few years and these ﬁ ndings represent a  further 
step in the right direction, although the ultimate prize 
Published Online
February 4, 2015
http://dx.doi.org/10.1016/
S1474-4422(15)70019-0
See Articles page 253
Comment
www.thelancet.com/neurology   Vol 14   March 2015 237
of a cure remains elusive. As Winston Churchill said, “It 
is always wise to look ahead, but diﬃ  cult to look further 
than you can see”.11 
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The systematic search for risk factors in multiple sclerosis 
Substantial advances in multiple sclerosis research 
have occurred in recent years, from the advent of oral 
therapies for relapsing-remitting multiple sclerosis1 
to the discovery of previously unknown genetic risk 
variants.2 Nevertheless, the cause or causes of multiple 
sclerosis continue to elude us. Susceptibility probably 
involves a combination of common genetic inheritance 
and environmental exposures, but the speciﬁ c elements 
remain unclear. Worldwide, as populations age, the 
prevalence of multiple sclerosis has also increased,3 
inﬂ icting immense costs, both personal and societal. 
There is an urgent need to get to the root of the problem, 
to develop eﬀ ective strategies aimed at prevention. These 
lofty goals cannot be achieved without a methodical 
assessment of the best available evidence as to what 
might cause multiple sclerosis, particularly those factors 
that are amenable to change. Belbasis and colleagues’ 
umbrella review in The Lancet Neurology4 represents 
decades of research into the environmental risk factors 
for multiple sclerosis, providing a rigorous and systematic 
assessment of published reviews and meta-analyses. 
Although not a new concept, an umbrella review has 
not been done in multiple sclerosis before; previous 
systematic reviews have typically focused on a single risk 
factor, making this mega-meta-analysis unique. 
Of the 20 reviews included, 17 contained 44 unique 
meta-analyses, with medians of 933 patients with 
multiple sclerosis and eight original studies per meta-
analysis.4 About half of the meta-analyses were related 
to vaccines or infections. Two environmental exposures 
showed credible evidence of a relation with multiple 
sclerosis: smoking and Epstein-Barr virus (the latter 
measured as IgG seropositivity for Epstein-Barr virus 
nuclear antigen or history of infectious mononucleosis). 
All three factors showed a consistent and signiﬁ cant 
association with multiple sclerosis, without suggestion 
of bias or large statistical heterogeneity (ie, the 
variability between the original study results was judged 
to be acceptable).
What does this mean for potential public health 
strategies to prevent multiple sclerosis? Both the 
Epstein-Barr virus risk factors had reasonable summary 
eﬀ ect sizes, with odds ratios greater than 2. However, 
more than 90% of the world’s population is positive for 
Epstein-Barr virus,5 and the possibility of developing 
a safe vaccine against a virus human beings have 
co-existed with for millennia is uncertain.6 Smoking 
appears more amenable to modiﬁ cation, but the 
eﬀ ect size was also more modest (odds ratio=1·52, 
95% CI 1·39–1·66) and smoking is already a target of 
many governmental health strategies.7 Nonetheless, 
counselling for family members or other individuals 
at higher than average risk of developing multiple 
sclerosis seems a pragmatic option.
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